Hybrid reproductive medicine and women’s health company Kindbody announced Tuesday that it is introducing at-home fertility hormone testing for both men and women.
The tests, which measure hormones related to reproductive function and health, can be combined with an in-person or virtual appointment with a Kindbody doctor to discuss the results.
The hormone tests are the first entry in the reproductive health company’s Kind at Home consumer products division.
“From day one, our vision has been healthcare consumerism. Our responsibility is to serve patients wherever they are: virtually, in the clinic, or at home. With the launch of Kind at Home, Kindbody connects the dots on the continuum of fertility care by providing high-quality virtual and in-person care from fertility assessment to postpartum,” said Founder and CEO Gina Bartasi in a statement.
WHY IT MATTERS
Infertility, defined as the inability to conceive after at least a year of unprotected sex, is relatively common. According to the CDC, about 6% of married women between the ages of 15 and 44 have difficulty conceiving after a year of trying.
Male fertility is also an important factor. In about 35% of couples experiencing infertility, a male factor is identified alongside a female factor. In about 8% of couples, a male factor is the only identified cause.
THE BIGGER TREND
In June, Kindbody announced that it had been raised $62 million in Series C funding, bringing the total raise to $122 million. Series C built on a Series B raise of $32 million as of July 2020.
Digital health startups serving women and others with female biology are reaping more funding, raising $1.3 billion by August 2021. according to a report by Rock Health. However, this is still a relatively small part of the overall digital health offerings that have boomed over the past year.
Other companies that focus on the fertility space include at-home testing company Proov raised $9.7 million in Series A funding last month, and kegg, a startup aiming to determine a fertile window by testing cervical fluid, raised $3 million in September. Carrot Fertility, which focuses on fertility benefits management and supplies medicines, raised $75 million in August.
Male fertility focused startups include Legacy and Dadi.